The Latest

An HIV testing event with Melanie Thompson alongside staff from the AIDS Research Consoritum of Atlanta (ARCA) and Fulton County, Georgia, HIV prevention workers

Leading HIV Scientist Eulogizes a Pioneering Atlanta-Based Research Organization

“ARCA started because there was a heartbreaking need for new drugs to treat HIV,” says Melanie Thompson, M.D. “The landscape for HIV research has indeed changed, largely as a result of our successes.”

By Terri Wilder, M.S.W.
green light

U.S. Waits on Approval of Long-Acting HIV Treatment Cabotegravir and Rilpivirine as European Union Gives the Green Light

The era of once-a-month HIV treatment has begun in the European Union—and it may soon commence in the U.S. as well. Long-acting pre-exposure prophylaxis (PrEP) is also on the horizon.

By Michael Broder
triptych of medical scientists performing lab and research duties

Top 10 HIV Clinical Developments of 2020

In this exclusive series of articles, David Alain Wohl, M.D., calls attention to 10 developments that have tremendous short-term implications for our day-to-day efforts to improve HIV prevention, treatment, patient care, and policy in the U.S., and analyzes each development with his trademark wit and clinical savvy.

By David Alain Wohl, M.D.
scientists analyzing

Fostemsavir, at Last: A New Treatment Option for Extensive HIV Drug Resistance

Most people living with HIV will never need fostemsavir. But for those who do, the drug can be a life-saver—and that is pretty epic.

By David Alain Wohl, M.D.

This Week in HIV Research: A Metabolic Maze

Oct. 29, 2020: Diabetes incidence on INSTIs vs. NNRTIs vs. protease inhibitors; can NRTIs fight diabetes?; from TDF to TAF in HIV/HBV-coinfected people; assessing neurocognitive impacts of older two-drug regimens.

By Barbara Jungwirth and Myles Helfand
scale and tape measure

Flurry of New Research Explores Weight Gain on Integrase Inhibitors Among People Living With HIV

Taken together, these studies appear to confirm that weight gain is a class effect of INSTIs, albeit with potential differences between individual drugs—and much left to be learned about the health impact.

By Michael Broder
medical scale

More Research Points to Weight Increases on TAF-Containing HIV Treatment

Although the mechanism and long-term implications remain unclear, these studies affirm that the effect is occurring—and that a person’s prior HIV treatment regimen may play a role.

By Michael Broder
Black man talking with his doctor in office.

B/F/TAF Holds Up as Switch Regimen for Black People Living With HIV, Including Those With Resistance

While the most striking aspect of the study was its demographic focus, the baseline resistance profile of the participants was also key.

By Michael Broder
busy hospital

To Increase Access to HIV Post-Exposure Prophylaxis, New York State Updated Its Guidelines for Clinicians

If you’re a provider in or outside the state, you’ll want to read these new guidelines.

By Terri Wilder, M.S.W.
pulling back curtain

This Week in HIV Research: Life in the Integrase Era

Aug. 6, 2020: Recent trends in drug interaction rates; integrase inhibitors and cardiac event risk; a deep dive into HIV drug resistance in Florida; frailty symptoms and neurocognitive disorders amidst high CD4 counts.

By Barbara Jungwirth and Myles Helfand